Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 5, 2024
Daily News
January 5, 2024
- Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?
January 5, 2024
- After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
- Moderna Seeks Japan Nod for Pre-Filled Syringe Form of COVID Vaccine
January 5, 2024
- Panels Urge OTC Switches “within 3 Years” for Drugs Sold Over the Counter in 2 or More Other Countries
January 5, 2024
- MHLW Unveils Draft Guidelines on Access to Intractable, Pediatric Disease Databases
January 5, 2024
- After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
January 5, 2024
- Astellas, China Biotech Hook Up on Bispecific Macrophage Engagers
January 5, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…